Skip to main content
VITRAFY LIFE SCIENCES LIMITED logo

VITRAFY LIFE SCIENCES LIMITED — Investor Relations & Filings

Ticker · VFY ISIN · AU0000361297 ASX Professional, scientific and technical activities
Open in API
Filings indexed 91 across all filing types
Latest filing 2026-01-27 Regulatory Filings
Country AU Australia
Listing ASX VFY

About VITRAFY LIFE SCIENCES LIMITED

https://www.vitrafy.com

Vitrafy Life Sciences Limited specializes in the development and commercialization of advanced cryopreservation technologies designed to optimize the preservation and transport of biological materials. The company provides end-to-end cold chain solutions, focusing on maintaining the viability and functionality of sensitive life science products, including cells, tissues, and organs. Its core technology utilizes precise, automated cooling and warming protocols to minimize cellular damage during the freezing process, addressing critical challenges in regenerative medicine, cell and gene therapy, and biobanking. By integrating hardware, software, and specialized consumables, Vitrafy aims to standardize cryopreservation workflows and improve clinical outcomes through enhanced sample recovery and data-driven monitoring throughout the supply chain.

Recent filings

Filing Released Lang Actions
Vitrafy Q2 FY26 Investor Briefing 1 page 184.1KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 28 January 2026 about an upcoming investor briefing for the Q2 FY26 results. It states that the Quarterly Activities Report and Appendix 4C will be released on 29 January 2026 and invites investors to attend the briefing. The document is short (2000 characters) and does not contain any actual financial data or detailed financial statements. It is primarily an announcement of a future event and report release, not the report itself. Therefore, it fits the criteria for a Regulatory Filings (RNS) category, which covers general regulatory announcements and miscellaneous filings that do not fit other categories.
2026-01-27 English
Appointment of Independent Non-Executive Director 2 pages 207.5KB
Board/Management Information Classification · 100% confidence The document is an ASX announcement dated 20 January 2026 regarding the appointment of a new Non-Executive Director, Dr. Jeannette Joughin, to the Board of Directors of Vitrafy Life Sciences Limited. It details her background, expertise, and the strategic value she brings to the company. There is no financial data, no discussion of financial results, no mention of a report being attached or published, and no regulatory certification or voting results. The content focuses solely on management/board changes. Therefore, the document fits the category of Board/Management Information (MANG). The document length is about 5,416 characters, which is consistent with a detailed announcement rather than a brief notice or a full report.
2026-01-19 English
Initial Director's Interest Notice 2 pages 263.8KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3X Initial Director’s Interest Notice' and references ASX listing rule 3.19A.1 and section 205G of the Corporations Act. It details the director's relevant interests in securities and contracts, with no securities held. This is a report of personal share transactions or interests by a company director. The document length is short and focused solely on director interests, matching the definition of Director's Dealing filings. Therefore, the appropriate classification is DIRS (Director's Dealing).
2026-01-19 English
Vitrafy Enters Strategic Commercial Agreement with IMV 3 pages 196.2KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 15 January 2026 about Vitrafy entering a strategic commercial agreement with IMV Technologies. It details the terms of the agreement, the background of the partner company, and the expected commercial and financial implications. There are no financial statements, quarterly or annual results, or detailed financial data presented. The document is a corporate announcement about a new commercial partnership and strategic collaboration, which fits the category of Capital/Financing Update (CAP) as it relates to business development and potential revenue generation. It is not an earnings release, annual report, or regulatory filing. The length is about 6939 characters, which is consistent with a detailed announcement but not a full report. Therefore, the best classification is Capital/Financing Update (CAP).
2026-01-14 English
IMV Strategic Partnership Investor Presentation 6 pages 250.9KB
Regulatory Filings Classification · 95% confidence The document is a detailed announcement about a strategic commercial agreement between Vitrafy Life Sciences Limited and IMV Technologies. It outlines the terms of the partnership, financial arrangements, market positioning, and strategic benefits. There are no financial statements, regulatory certifications, voting results, or management changes. The content is focused on a business partnership and commercial collaboration rather than financial reporting or regulatory filings. The document length is under 5,000 characters and is a standalone announcement of a strategic partnership, not a report or presentation for investors. Therefore, it does not fit categories like Annual Report, Interim Report, Earnings Release, or Investor Presentation. It is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement that does not fit other specific categories.
2026-01-14 English
IMV Strategic Commercial Agreement Investor Briefing 1
Investor Presentation Classification · 90% confidence The document is an ASX announcement dated 15 January 2026 about a briefing for investors regarding a Strategic Commercial Agreement between Vitrafy Life Sciences and IMV Technologies. It invites investors to a webinar to discuss the agreement and answer questions. The document does not contain financial statements, detailed financial data, or regulatory filings. It is an announcement of an investor briefing related to a commercial agreement, which fits the category of an Investor Presentation (IP) since it focuses on financials, strategy, and market position through a briefing format.
2026-01-14 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.